12th-14th September, 2016

London

Speakers

Expand/Collapse

Alastair Brown
Head of Pharmacology
Heptares

Day One

Tuesday 13th September 2016

10:00 | Panel Discussion: Achieving the Goal of Cost Effective, Non-Invasive Biomarkers

Day Two

Wednesday 14th September 2016

15:45 | Opportunities & Challenges in the Biotech World

Birgitte Søgaard
Divisional Director, Clinical & Quantitative Pharmacology
Lundbeck

Day Two

Wednesday 14th September 2016

09:30 | Why Biomarkers are Key Prior to Pivotal Trials to Guide Dose & Efficacy in AD Patients

Carsten Spannhuth
Global Program Medical Director & Digital Development Medical Adviser
Novartis

Day Two

Wednesday 14th September 2016

12:00 | Panel Discussion: Addressing the Clinical Trial Landscape

11:30 | Harnessing Big Data & Wearable Technology to Advise Clinical Readouts

Claudio Babiloni
Associate Professor of Physiology
University of Rome “La Sapienza”

Day Two

Wednesday 14th September 2016

10:00 | Back-Translation of Cortical EEG Biomarkers from Humans to Mice for Drug Discovery in Alzheimer’s Disease: The PharmaCog Project Way

Craig Ritchie
Professor of the Psychiatry of Aging, University of Edinburgh & Project Co-ordinator
EPAD

Day One

Tuesday 13th September 2016

09:30 | If Precision Medicine in Dementia Prevention in Our Destination, How do We Get There?

Cyrille Sur
Executive Director & Neuroscience Imaging Lead
Merck

Day One

Tuesday 13th September 2016

14:30 | [18F]MK-6240, A Novel Tau PET Tracer: From Discovery to Clinical Evaluation

David Reynolds
Chief Scientific Officer
Alzheimer’s Research UK

Day One

Tuesday 13th September 2016

16:00 | Breakout Roundtable Discussion: Evolving Science in Neurodegeneration

Eric Karran
Vice President, Distinguished Research Fellow, Foundational Neuroscience Center
AbbVie

Workshop

September 12, 2016

14:00 | Rethinking the Amyloid Beta Cascade Hypothesis & its Targeting for Disease Modification in Alzheimer’s Disease

Day Two

Wednesday 14th September 2016

09:00 | Alzheimer’s Disease Therapeutics: Possibilities & Pitfalls

Fabio Blandini
 Director, Center for Research in Neurodegenerative Diseases
 IRCCS C. Mondino National Neurological Institute

Day One

Tuesday 13th September 2016

12:50 | Panel Discussion: Debating Pre-Clincal Translational Modelling in Neurodegeneration

Garry Honey
Head of Biomarkers & Clinical Imaging
Roche

Day One

Tuesday 13th September 2016

10:00 | Panel Discussion: Achieving the Goal of Cost Effective, Non-Invasive Biomarkers

08:30 | Developing Novel, Accurate Clinical Diagnostic & Disease Progression Biomarkers

Harald Hampel
Professor, AXA Research Fund & UPMC Chair
Sorbonne Universities, Pierre & Marie Curie University

Day One

Tuesday 13th September 2016

10:00 | Panel Discussion: Achieving the Goal of Cost Effective, Non-Invasive Biomarkers

Day Two

Wednesday 14th September 2016

14:15 | The Precision Medicine Paradigm in Neurodegenerative Diseases

Helle Sickmann
Clinical Pharmacology Scientist
Lundbeck

Day One

Tuesday 13th September 2016

10:00 | Panel Discussion: Achieving the Goal of Cost Effective, Non-Invasive Biomarkers

09:00 | Translational Perspectives on Biomarker Discovery & Development in AD

Jan Grimm
CSO
Neurimmune Holding AG

Day Two

Wednesday 14th September 2016

13:45 | Targeting the Spread of Pathology in Neurodegenerative Diseases

Johan Luthman
Vice President, Neuroscience Clinical Development
Eisai

Day Two

Wednesday 14th September 2016

12:00 | Panel Discussion: Addressing the Clinical Trial Landscape

11:00 | Maximising the Translatability of Early Development Proof of Principle Trials

Jonathan Brotchie
Founder & President
Atuka Inc

Day One

Tuesday 13th September 2016

12:30 | Non-Human Primate Models of Motor Symptoms, Cognitive Dysfunction & Molecular Pathology of Parkinson’s Disease

Kate Bingham
Managing Partner
SV Life Sciences

Day One

Tuesday 13th September 2016

16:00 | Breakout Roundtable Discussion: Evolving Science in Neurodegeneration

Richard Wade-Martins
Professor of Molecular Neuroscience
University of Oxford

Day One

Tuesday 13th September 2016

11:30 | Advancing Human iPSC Models for Translational Research

Robert O’Donnell
Vice President, Global Regulatory Head
Johnson & Johnson

Day Two

Wednesday 14th September 2016

12:00 | Panel Discussion: Addressing the Clinical Trial Landscape

Samuel Agus
Chief Specialist, Medical Affairs, Neurology
Lundbeck

Day One

Tuesday 13th September 2016

17:15 | Chair’s Closing Remarks

08:20 | Chairman’s Opening Remarks & Keynote Presentation

Suchira Bose
Principal Research Scientist
Eli Lilly & Company

Suchira Bose has a background in protein folding/ mis-folding and molecular chaperones. Following her Ph.D she obtained a long-term EMBO fellowship to understand the molecular mechanisms of Hsp90 function at the University of Regensburg, Germany. She then completed her postdoctoral training at the University of Bristol, where she studied the role of post-translational modification on proteasome function. She joined Lilly Neuroscience in 2001 and has 15 years of experience in neurodegeneration research and drug discovery with expertise in pre-clinical models and target validation.  She is currently a Principal Research Scientist heading an in vitro team in the Neurodegeneration/Molecular Pathology Team, focusing on protein mis-folding and neurodegenerative diseases including tau and synuclein pathology.

Day One

Tuesday 13th September 2016

15:00 | Reviewing Tau as a Therapeutic Strategy in Neurodegenerative Diseases

Susan Browne
Director, CNS Discovery
Teva Pharmaceuticals

Day One

Tuesday 13th September 2016

12:50 | Panel Discussion: Debating Pre-Clincal Translational Modelling in Neurodegeneration

12:00 | The Conundrum of Modifying Neurodegeneration in a Mouse: Optimizing Pre-Clinical Approaches to Improve Probability of Clinical Success

Tiago Outeiro
Professor & Director, Department of Neurodegeneration and Neurorestoration
University Medical Center Gottingen

Day One

Tuesday 13th September 2016

16:00 | Breakout Roundtable Discussion: Evolving Science in Neurodegeneration

Day Two

Wednesday 14th September 2016

15:15 | From the Bench to the Bedside: Exploiting Targets for Therapeutic Intervention in Neurodegeneration

Tobias Hartmann
Professor, Experimental Neurology
Saarland University

The German Institute for Dementia Prevention, led by Prof. Dr. rer. nat. Tobias Hartmann, focuses is the development of innovative preventive approaches to Alzheimer’s disease and their practical implementation. The institute’s research spans a wide array of activities, they are best known for their long-standing scientific contribution on the role of lipid metabolic pathways and nutrition in AD pathogenesis and prevention. Previous work includes CSF amyloid biomarkers, statins/cholesterol, identification of Alzheimer’s disease related molecular pathways  and intracellular amyloid biology. Hartmann published over 120 articles on Alzheimer’s disease. Most recently, the LipiDiDiet clinical trial highlights multi-nutrient intervention resulting in clinical benefits for early Alzheimer’s disease.

Day One

Tuesday 13th September 2016

16:00 | Breakout Roundtable Discussion: Evolving Science in Neurodegeneration

Daniel Michaelson
Professor of Neurobiology
Tel Aviv University

Daniel M. Michaelson is Professor of Neurobiology at the  Faculty of Life Sciences at Tel Aviv University. He graduated from  the Hebrew university in Jerusalem with a  BSc in Physics and mathematics in 1968.  Following this, he was a Fulbright –Hayes fellow  and obtained  a PhD in Biophysics form the University of California Berekely in 1973 . His post doctoral training was in neurochemistry at the labortatory of  Professor  M.A. Raftery at the California Institute of Technology where he studied the nictonic acetylcholine receptors and  it's functional  reconstitution  He joined the faculty of life science at Tel Aviv university in 1974  where his research first focused on the mechanisms underlying neurotransmitter release. His current research focuses  on Alzheimer's disease and the mechanisms underlying the effects of genetic risk factors of the disease and their crosstalk with environmental factors . Specifically the research focuses on apolipoprotein E4, which is the most prevalent gentic risk factor of Alzheimers disease, and on the development of therapeutic approaches to counteract its pathological effects. He was the first director of the Tel Aviv Iniversity Rabin Institute for neurobiology and is the incumbent of the Lebach chair in molecular Neurodegenration.

Day One

Tuesday 13th September 2016

16:00 | Breakout Roundtable Discussion: Evolving Science in Neurodegeneration